A retrospective analysis of phase 1 oncology studies that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development and biopsy sample collection.
A retrospective analysis of about 72 phase 1 oncology studies, conducted between 2003 and 2010, that used biopsy-derived pharmacodynamic biomarkers, could not draw a correlation between subsequent drug development or drug use and biopsy sample collection.
Starting with literature review that identified nearly 5000 phase 1 oncology trials conducted during the 7-year period, the authors narrowed their study to 72 trials that use a biomarker. About 1873 biopsies were documented in the 72 studies, and only 12 of these studies reported having a significant biomarker result. Only 4 of the 12 studies were referenced by subsequent publications and the maximum tolerated dose from those studies was applied in future drug development. An important consideration is that 14 of the 72 studies did not mention the number of biopsies that were performed, which would mean that 1873 is possibly a lower estimate of the total number of biopsies conducted in these studies.
According to senior study author Mark Ratain, MD, professor of medicine at the University of Chicago, their study “calls into question the increasing use of such biomarkers in phase 1 studies. The process has had little or no impact on drug development or dose decisions.” He went on to describe the tricky situation that patient’s face: if they want to receive an investigational drug, they are forced to consent to sharing their tissue samples. Hailing action from institutional review boards that review these studies, Ratain said, “Institutional review boards should consider whether such exploratory tissue sampling is even ethical.” He went on to suggest that the primary objective of trials that collect biopsy samples should not be pharmacodynamic evaluation, rather, it should ascertain the effect of drug on the biomarker.
Published in the Journal of Clinical Oncology, the study also draws attention to the unnecessary cost associated with collecting and analyzing biopsy samples that cannot be associated with fruitful outcomes. Depending on the site of the tissue, a biopsy could cost a health system anywhere from $1000 to $10,000. One such study analyzed the Medicare utilization rates for biopsies in lung cancer patients and found that between 2009 and 2011, biopsy costs in lung cancer patients with an abnormal chest CT scan who had negative biopsies touched $16.5 million. The average cost of a biopsy in these patients was $3558. A core-needle biopsy in breast cancer patients is estimated at $483.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More